GNLX — GENELUX Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1231457 ·
Last close
$2.48
Market Cap
$112.21M
52W High
$8.53
52W Low
$2.29
ADV30
304,293
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -9,645,000 | -9,471,000 | 26,205,000 | 9,184,000 | 10,092,000 |
| Mar 2026 | 0 | — | -9,171,000 | -8,928,000 | 32,372,000 | 9,273,000 | 9,451,000 |
| Dec 2025 | 8,000 | — | -9,412,000 | -9,247,000 | 19,027,000 | 5,333,000 | 7,483,000 |
| Sep 2025 | 0 | — | -8,194,000 | -7,950,000 | 24,987,000 | 3,692,000 | 6,396,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,892,000
Investing CF
$93,000
Financing CF
$18,866,000
CapEx
$-1,989,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-292,466,000
Inventory
—
Receivables
—
ST Investments
$16,936,000
EBIT TTM
$-34,569,000
Pretax Income TTM
$-33,581,000
Interest Exp TTM
$0
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,000
EBITDA
$-36,280,000
Free Cash Flow
$-15,252,750
Enterprise Value
$95,331,888
Total Cash
$18,670,000
Total Debt
$2,420,000
Shares Out
45,245,335
Trailing EPS
$-0.86
Book Value
$0.36
ROE
-177.9%
ROA
-77.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,000 | -33,214,000 | -32,145,000 | 19,027,000 | 7,483,000 | 11,544,000 | -25,268,000 |
| Dec 2024 | 8,000 | -31,696,000 | -29,869,000 | 34,716,000 | 8,442,000 | 26,274,000 | -21,228,000 |
| Dec 2023 | 170,000 | -24,165,000 | -28,297,000 | 27,893,000 | 8,420,000 | 19,473,000 | -20,275,000 |
| Dec 2022 | 11,068,000 | -3,013,000 | -5,207,000 | 5,531,000 | 41,314,000 | -35,783,000 | -3,571,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.74
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.45 · call volume: 1 · put volume: 20
Expected Move to 2026-10-16:
±$0.99
(40.41%) —
implied range
$1.46 –
$3.44
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTOR | CITIUS ONCOLOGY, INC. | $111.05M | $1.05 | — |
| AARD | Aardvark Therapeutics, Inc. | $110.74M | $5.06 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $114.02M | $7.61 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $109.36M | $9.57 | — |
| QUCY | Quantum Cyber N.V. | $115.17M | $1.37 | — |
News headlines (Yahoo Finance, 1h cache)
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
2026-08-13 20:20 · Yahoo
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
2026-06-30 12:00 · Yahoo
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
2026-05-07 20:15 · Yahoo
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
2026-09-09 20:01 · Yahoo
Attovia Therapeutics Appoints John W. Smither to Board of Directors
2026-07-15 12:30 · Yahoo
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-03-19 20:15 · Yahoo
Genelux Corporation to Participate in Upcoming Conferences
2026-02-18 13:00 · Yahoo
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
2026-01-12 21:00 · Yahoo
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
2026-01-08 14:13 · Yahoo
Genelux Corporation Announces Proposed Public Offering of Common Stock
2026-01-07 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.